Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.

ABSTRACT:

SUBMITTER: Li G 

PROVIDER: S-EPMC9183219 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature